In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
(Washington, D.C.) — As Congress begins to examine high prescription drug prices, the Pharmaceutical Care Management Association (PCMA) sent letters to several congressional committees highlighting the value pharmacy benefit managers (PBMs) provide to patients and payers as well as outlining
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a Medicare Part D report released today by the Office of Inspector (OIG), U.S. Department of Health and Human Services (HHS): “This report finally debunks the myth
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) supports the Centers for Medicare and Medicaid Services’ (CMS) proposal to promote the use of biosimilars in Medicare Part D. Pharmacy benefit companies, or PBMs, have long supported the development of
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. Pandemic Vaccine: Safety Top Priority for Rx Supply Chain… As states
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from the IQVIA Institute that shows net prescription spending is decreasing in settings in which pharmacy benefit management (PBM) tools are widely used.
Conversation on “Improving Competition to Lower Drug Prices” Emphasizes Need to Stop Abuse of the Patent System Last week, The Hill hosted an event titled, “Prescription for Change: Improving Competition to Lower Drug Prices.” During the event, lawmakers and a panel of drug
©2024 PCMA. All Rights Reserved.
